NEXGEL, Inc. (NXGL)
NASDAQ: NXGL · Real-Time Price · USD
2.490
-0.150 (-5.68%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Company Description

NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States.

It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions.

It also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment.

In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Lumagel Beauty, Kenkoderm and Silly George brand names.

The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019.

NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.

NEXGEL, Inc.
NEXGEL logo
Country United States
Founded 1997
IPO Date Dec 22, 2021
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 19
CEO Adam Levy

Contact Details

Address:
2150 Cabot Boulevard West, Suite B
Langhorne, Pennsylvania 19047
United States
Phone 215 702 8550
Website nexgel.com

Stock Details

Ticker Symbol NXGL
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.50
CIK Code 0001468929
CUSIP Number 65344E107
ISIN Number US65344E1073
Employer ID 26-4042544
SIC Code 3841

Key Executives

Name Position
Adam R. Levy Chief Executive Officer, President and Director
Joseph F. McGuire Chief Financial Officer
Gregory Robb Vice President of Operations

Latest SEC Filings

Date Type Title
Apr 10, 2025 144 Filing
Mar 27, 2025 10-K Annual Report
Mar 25, 2025 8-K Current Report
Mar 24, 2025 8-K Current Report
Jan 22, 2025 8-K Current Report
Jan 6, 2025 8-K Current Report
Jan 2, 2025 144 Filing
Dec 20, 2024 144 Filing
Nov 14, 2024 8-K Current Report
Nov 13, 2024 10-Q Quarterly Report